Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of SHR-7787 injection in advanced malignant solid tumors
CTR20243532Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-7787 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Oct 2024; status: active.
02
Drugs
SHR-7787
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243532.